Use of HER2 gene amplification to identify patients with metastatic colorectal cancer resistant to anti-EGFR monoclonal antibodies.

被引：4
|
作者：
Barbara, Cecilia
Martin, Vittoria
Molinari, Francesca
Landi, Lorenza
Riva, Alice
Saletti, Piercarlo
de Dosso, Sara
Geva, Ravit
Tejpar, Sabine
Fountzilas, George
Kalogeras, Konstantine T.
Frattini, Milo
Cappuzzo, Federico
机构：
[1] Osped Civile Livorno, Dept Med Oncol, Livorno, Italy
[2] Ist Cantonale Patol, Lab Mol Diagnost, Locarno, Switzerland
[3] Osped San Giovanni Bellinzona, Oncol Inst Southern Switzerland, Bellinzona, Switzerland
[4] Oncol Inst Southern Switzerland, Bellinzona, Switzerland
[5] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel
[6] Univ Hosp Gasthuisberg, Leuven, Belgium
[7] Hellen Cooperat Oncol Grp, Athens, Greece
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 04期
关键词：
D O I：
10.1200/jco.2012.30.4_suppl.474
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
474
引用
收藏
页数：2
相关论文
共 50 条
  • [21] HeR2 Signaling and Resistance to the Anti-EGFR Monoclonal Antibody Cetuximab: A Further Step toward Personalized Medicine for Patients with Colorectal Cancer
    Ciardiello, Fortunato
    Normanno, Nicola
    CANCER DISCOVERY, 2011, 1 (06) : 472 - 474
  • [22] Beyond KRAS:Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer
    Alfonso De Stefano
    Chiara Carlomagno
    World Journal of Gastroenterology, 2014, (29) : 9732 - 9743
  • [23] Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer
    De Stefano, Alfonso
    Carlomagno, Chiara
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (29) : 9732 - 9743
  • [24] EGFR gene copy number as a predictive biomarker for resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer treatment:a meta-analysis
    Wei-Dong Shen
    Hong-Lin Chen
    Peng-Fei Liu
    ChineseJournalofCancerResearch, 2014, 26 (01) : 59 - 71
  • [25] Use of anti-EGFR antibodies (cetuximab and panitumumab) in the treatment of metastatic colorectal cancer in KRAS wild type patients
    Smith, D.
    Bosacki, C.
    Merrouche, Y.
    BULLETIN DU CANCER, 2009, 96 : S31 - S40
  • [26] EGFR gene copy number as a predictive biomarker for resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer treatment: a meta-analysis
    Shen, Wei-Dong
    Chen, Hong-Lin
    Liu, Peng-Fei
    CHINESE JOURNAL OF CANCER RESEARCH, 2014, 26 (01) : 59 - 71
  • [27] Biomarker selection of liver metastatic colorectal patients for anti-EGFR monoclonal antibodies: A machine learning analysis
    Chen, Y.
    Chang, W.
    Wei, Y.
    Xu, J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [28] Comprehensive analysis of egfr and its downstream pathways deregulation identifies the vast majority of metastatic colorectal cancer (mCRC) patients resistant to anti-egfr monoclonal antibodies (MoAbs)
    Frattini, M.
    Molinari, F.
    De Dosso, S.
    Martin, V
    Crippa, S.
    Saletti, P.
    Mazzucchelli, L.
    VIRCHOWS ARCHIV, 2009, 455 : 46 - 46
  • [29] HER2 positivity as a biomarker for poor prognosis and unresponsiveness to anti-EGFR therapy in colorectal cancer
    Huang, Wenbai
    Chen, Yijiao
    Chang, Wenju
    Ren, Li
    Tang, Wentao
    Zheng, Peng
    Wu, Qi
    Liu, Tianyu
    Liu, Yu
    Wei, Ye
    Xu, Jianmin
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (04) : 993 - 1002
  • [30] Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer
    Zacharenia Saridaki
    Vassilis Georgoulias
    John Souglakos
    World Journal of Gastroenterology, 2010, 16 (10) : 1177 - 1187
12345